Dopavision announces topline results for MyopiaX trial for slowing paedatric myopia progression


The light-based therapy functions using a virtual reality headset

A young person tries on glasses in front of a mirror. Image credit: ©eakgrungenerd –

The trial will be conducted at test sites in six European countries. ©eakgrungenerd –

Dopavision, a health technology company based in Berlin, Germany, has announced topline findings from its proof-of-concept clinical trial investigating the safety and tolerability of MyopiaX, which delivers targeted photobiomodulation to the eye for managing the progression of paediatric myopia, according to a news release. The trial was conducted across six European countries. Data from the trial found that MyopiaX proved clinically safe and tolerable, in addition to showing clinical effect on the rate of myopia progression.1

“The 6 month outcomes represent a significant step in the clinical development of MyopiaX,” said Ian Flitcroft, PhD, FRCOphth, coordinating investigator of the MyopiaX-1 trial, in the release. “The results are an important addition to the existing evidence supporting the mechanism of action of MyopiaX light stimulation.”

MyopiaX is a non-invasive, light-based treatment that utilises a virtual reality headset and wireless controller to deliver treatment while paediatric patients engage with digital content that is age appropriate.2 The treatment stimulates specific cells in the eye to regulate innate signaling pathways, which then works to slow the rate of myopia progression.1

The 6-month, randomised, multicentre controlled trial consists of 124 children with myopia between the ages of 6 and 12 that experienced a refractive error starting at -0.75 D, had no previous or current myopia treatment of participation in other trials, no other eye conditions or illnesses affecting the eye and no medical or family history of photosensitive epilepsy.2 Some exclusions from the trial include patients with anisometropia at≥ 1.5 D, astigmatism at ≥ 3 D, suspicion of syndromic or monogenetic myopia and any illnesses affecting dopamine function, among others.3

Trial participants were randomised in 2:1 ratio to MyopiaX or the control group. Participants assigned to MyopiaX used the treatment twice daily at home for 12 months. After 6 months, the participants wore myopia control spectacles. The control group only wore myopia control spectacles for 12 months. Participants also brought in for five clinic visits during their treatment period.2

“The 6-month findings of the MyopiaX-1 trial mark a monumental achievement for Dopavision,” said Mark Wuttke, PhD, CEO of Dopavision, in the release. “With MyopiaX, our goal is to enrich myopia management for millions of children worldwide, providing a safe, non-invasive and engaging alternative that empowers young people to build a healthier, brighter future.”

The clinical trial is ongoing and expected to be completed in September 2024. Dopavision is currently discussing potential pathways for MyopiaX’s development and approval with regulatory authorities, according to the company.1


  1. Dopavision announces topline results in clinical trial of targeted photobiomodulation approach for progressive myopia. News release. Dopavision. May 28, 2024. Accessed May 28, 2024.
  2. Clinical Trial. Dopavision. Accessed May 28, 2024.
  3. MyopiaX treatment for the reduction of myopia progression in children and adolescents: Safety and efficacy investigation (MyopiaX-1). Dopavision GmbH. NCT04967287. Updated February 20, 2024. Accessed May 28, 2024.
Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.